Ingrid M.E. Desar

The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer

Udai Banerji, D. Ross Camidge, Henk M.W. Verheul et al. · Clinical Cancer Research · 2010 · 210 citations

Medicine, Clinical Pharmacokinetics, Pharmacology +13

Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients

Ingrid M.E. Desar, Joannes F.M. Jacobs, Christina A. Hulsbergen‐vandeKaa et al. · International Journal of Cancer · 2010 · 135 citations · Full text

Life Sciences, Immunology, Oncology +17

Phase 2 Study of Lutetium 177–Labeled Anti–Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma

Marye J. Boers‐Sonderen, Tim J. van Oostenbrugge, Otto C. Boerman et al. · European Urology · 2015 · 104 citations

Medicine, Oncology, Pharmacology +15

Expression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8+ lymphocytes in primary sarcomas is subtype dependent

Anke van Erp, Yvonne M.H. Versleijen‐Jonkers, Melissa H.S. Hillebrandt-Roeffen et al. · Oncotarget · 2017 · 98 citations · Full text

Life Sciences, Immunology, Oncology +17

Phase 1 Radioimmunotherapy Study with Lutetium 177–labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma

Alexander B. Stillebroer, Otto C. Boerman, Ingrid M.E. Desar et al. · European Urology · 2012 · 97 citations

Medicine, Oncology, Pharmacology +12